Search Site

Lawrence S. Honig, MD, PhD

  • Professor of Neurology (in the Gertrude H. Sergievsky Center and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain) at CUMC
Lawrence S. Honig, MD, PhD

Lawrence Honig, MD, PhD, is a Professor of Clinical Neurology at Columbia University College of Physicians and Surgeons (New York, NY), in the Department of Neurology (Division of Aging and Dementia), Taub Institute for Research on Alzheimer's Disease and the Aging Brain, and the Gertrude H. Sergievsky Center. He is Director of the Clinical Core of the Alzheimer's Disease Research Center at Columbia University.

Dr. Honig obtained his MD medical degree from the University of Miami (Miami, Florida), and his PhD from the University of California at Berkeley (Berkeley, California). He underwent postgraduate internship in Medicine and residency in Neurology training at Stanford University Medical Center (California). He served on the faculty of the Neurology departments at Stanford University Medical Center, and then at the University of Texas Southwestern Medical Center in Dallas, prior to his arrival at Columbia University in the year 2000. His research interests are in Alzheimer's Disease, Lewy Body Dementia, Frontotemporal Dementia, Creutzfeldt-Jakob disease, and other disorders of nervous system aging and degeneration. In addition to directing the Clinical Core of the Alzheimer's Disease Research Center at Columbia University, he conducts a number of clinical drug study trials, and also engages in clinical patient care at NewYork-Presbyterian Hospital and at the Lucy G. Moses Center for Memory and Behavioral Disorders, in the Neurological Institute.

Dr. Honig's research interests are in Alzheimer's Disease, Lewy Body Dementia, Frontotemporal Dementia, Creutzfeldt-Jakob disease, and other disorders of nervous system aging and degeneration. In addition to directing the Clinical Core of the Alzheimer's Disease Research Center at Columbia University, he conducts a number of clinical drug study trials, and also engages in clinical patient care at New York Presbyterian Hospital and at the Lucy G. Moses Center for Memory and Behavioral Disorders, in the Neurological Institute.

Departmental Appointments

  • Department of Neurology
    Division of Aging and Dementia

Languages Spoken

(in addition to English)

  • Spanish
  • French

Education & Training

  • University of Miami School of Medicine
  • Internship: Stanford University School of Medicine
  • Residency: Stanford University School of Medicine

Centers/Institutes/Programs

  • Gertrude H. Sergievsky Center
  • Taub Institute for Research on Alzheimer's Disease and the Aging Brain

NIH Grants

  • IMAGING DEMENTIA EVIDENCE FOR AMYLOID SCANNING (IDEAS) STUDY: A COVERAGE WITH EVIDENCE DEVELOPMENT LONGITUDINAL COHORT STUDY (Private)

    Jan 1 2016 - Dec 31 2022

    A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTIPLE DOSE STUDY TO ASSESS EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ABBV-8E12 IN PROGRESSIVE SUPRANUCLEAR PALSY (P&S Industry Clinical Trial)

    Jun 23 2017 - Jun 23 2022

    A LONG-TERM EXTENSION STUDY OF THE SAFETY AND TOLERABILITY OF RVT-101 IN SUBJECTS WITH DEMENTIA WITH LEWY BODIES (DLB) (P&S Industry Clinical Trial)

    May 10 2017 - May 10 2022

    TARGETING LEWY BODY SPECIFIC PATHOLOGY USING BIOMARKERS (Federal Gov)

    Sep 30 2016 - Aug 31 2021

    A PHASE IB, MULTICENTER, RANDOMIZED,PLACEBO-CONTROLLED, DOUBLE-BLIND,PARALLEL-ARM, MULTIPLE-DOSE STUDY TO ASSESS THE SAFETY, TOLERABILITY, ANDPHARMACOKINETICS OF INTRAVENOUS CRENEZUMAB ADMINISTERED IN PATIENTS WITH MILD TO MODERATE ALZHEIMER''S DISEASE (P&S Industry Clinical Trial)

    Mar 16 2015 - Mar 16 2020

    AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF LU AE58054 AS ADJUNCTIVE TREATMENT TO ACETYLCHOLINESTERASE INHIBITORS IN PATIENTS (P&S Industry Clinical Trial)

    Dec 3 2014 - Dec 3 2019

    A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, 26-WEEK, PHASE 3 STUDY OF TWO DOSES OF EVP-6124 OR PLACEBO IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER''S DISEASE CURRENTLY OR PREVIOUSLY RECEIVING AN (P&S Industry Clinical Trial)

    Jun 16 2014 - Jun 16 2019

    LONGITUDINAL EVALUATION OF FAMILIAL FRONTOTEMPORAL DEMENTIA SUBJECTS (LEFFTDS) (Federal Gov)

    Sep 30 2014 - May 31 2019

    LONG LIFE FAMILY STUDY: COLUMBIA UNIVERSITY (Federal Gov)

    May 1 2014 - May 31 2019

    ASSESSMENT AND CHARACTERIZATION OF NAMING IN OLDER ADULTS WITH EPILEPSY (Federal Gov)

    Apr 1 2014 - Mar 31 2019

    RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, 18-MONTH SAFETY AND EFFICACY STUDY OF LEUCO-METHYLTHIONINIUM BIS(HYDROMETHANESULFONATE) IN SUBJECTS WITH MILD ALZHEIMER''S DISEASE (P&S Industry Clinical Trial)

    Mar 31 2014 - Mar 31 2019

    EFFECT OF PASSIVE IMMUNIZATION ON THE PROGRESSION OF MILD ALZHEIMER''S DISEASE: SOLANEZUMAB (LY2062430) VERSUS PLACEBO (P&S Industry Clinical Trial)

    Feb 14 2014 - Feb 14 2019

    A PHASE II/III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF 2 POTENTIAL DISEASE MODIFYING THERAPIES IN INDIVIDUALS AT RISK FOR AND WITH DOMINANTLY INHERITED ALZHEIMER''S DISEASE (P&S Industry Clinical Trial)

    Dec 23 2013 - Dec 23 2018

    A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY EXTENSION OF PHASE II STUDIES ABE4869G AND ABE4955G IN PATIENTS WITH MILD TO MODERATE ALZHEIMER''S DISEASE (P&S Industry Clinical Trial)

    Jul 23 2013 - Jul 23 2018

    A PHASE 2, RANDOMIZED, DOUBLE BLIND PLACEBO CONTROLLED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF PF-04360365 (PONEZUMAB) IN ADULT SUBJECTS WITH PROBABLE CEREBRAL AMYLOID ANGIOPATHY (P&S Industry Clinical Trial)

    Jul 18 2013 - Jul 18 2018

    CENTER OF EXCELLENCE IN ALZHEIMER DISEASE (NYS) (NY State Gov)

    Jul 1 2016 - Feb 28 2017

    GENENTECH ABE4869G (P&S Industry Clinical Trial)

    Oct 10 2011 - Oct 10 2016

    ACC-001-ALZ-2001 (P&S Industry Clinical Trial)

    Sep 29 2011 - Sep 29 2016

    H8A-MC-LZAO (P&S Industry Clinical Trial)

    Aug 25 2011 - Aug 25 2016

    A PHASE 2,RANDOMIZED DOUBLE-BLIND,PLACEBO-CONTROLLED,STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE TREATMENT OF PRGRE (P&S Industry Clinical Trial)

    Nov 4 2010 - Nov 4 2015

    ALZHEIMER S DISEASE NEUROIMAGING INITIATIVE, (ADNI) (Federal Gov)

    Jun 1 2005 - Aug 31 2015

    NATIONAL ALZHEIMER S COORDINATING CENTER (Federal Gov)

    Jul 1 2014 - Jun 30 2015

    ELI LILLY-H6L-MCLFBF (P&S Industry Clinical Trial)

    Jun 30 2010 - Jun 30 2015

    A PHASE 3 EXTENSION, MULTICENTER, DOUBLE-BLIND, LONG TERM SAFETY AND TOLERABILITY TREATMENT TRIAL OF BAPINEUZUMAB (P&S Industry Clinical Trial)

    Mar 5 2010 - Mar 5 2015

    A LONG-TERM FOLLOW-UP STUDY OF ORAL ELND005(AZD-103) IN SUBJECTS WITH ALZHEIMER''S DISEASE (P&S Industry Clinical Trial)

    Mar 4 2010 - Mar 4 2015

    MAGNETIC RESONANCE SPECTROSCOPY (MRS) TO ASSESS PROGRESSION OF ALZHEIMER DISEASE (AD) (Private)

    Aug 1 2012 - Jan 31 2015

    A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF THE SAFETY TOLERABILITY PHARMACODYNAMIC (P&S Industry Clinical Trial)

    Jan 8 2010 - Jan 8 2015

    PROTOCOL-H8A-MC-LZAM: EFFECT OF LY2062430, AN ANTI-AMYLOID BETA MONOCIONAL ANTIBODY ON THE PROGRESSION OF ALZHEIMERS (P&S Industry Clinical Trial)

    Nov 2 2009 - Nov 2 2014

    AN OPEN-LABEL,NON RANDOMIZED, MULTICENTER STUDY TO OPTIMIZE IMAGE ASSESSMENT AND EVALUATE THE EFFICACY AND SAFETY OF BAY (P&S Industry Clinical Trial)

    Jul 1 2009 - Jul 1 2014

    SUPPLEMENTAL POSITRON EMISSION TOMOGRAPHY SUBSTUDY PROTOCOL TO CLINICAL RESEARCH PROTOCOLS ELN115727-301-302 (P&S Industry Clinical Trial)

    Jun 30 2009 - Jun 30 2014

    NATIONAL ALZHEIMER S COORDINATING CENTER (NACC) - YEAR 15 (Federal Gov)

    Jul 1 1999 - Jun 30 2014

    NATIONAL ALZHEIMER S COORDINATING CENTER (NACC) - YR 15 (Federal Gov)

    Jul 1 1999 - Jun 30 2014

    ELAN -- ELND005 AD20 (P&S Industry Clinical Trial)

    Apr 28 2008 - Oct 31 2013

    LILLY LFAN (P&S Industry Clinical Trial)

    Aug 14 2008 - Mar 31 2013

    LP PATIENT EXPERIENCE SURVEY (Private)

    Oct 18 2011 - Oct 17 2012

    COMBINED CSF BIOMARKERS AND GBA GENOTYPE FOR DIAGNOSIS OF LB D (Private)

    Mar 1 2010 - Jun 30 2012

    CHANGES IN TELOMERE LENGTH AND THE RISK OF ALZHEIMER DISEASE (Private)

    Nov 1 2008 - Oct 31 2011

    DEVELOPMENT OF NOVEL BIOMARKERS FOR ALZHEIMER''S DISEASE (Federal Gov)

    May 7 2009 - Jan 31 2010